Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

nexthorizon

  • Home
  •  
  • nexthorizon



  • Most Read
  • Latest Comments
  • Imugene partners with multi billion dollar global pharma company, Merck & Co for new trial
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Imugene partners with multi billion dollar global pharma company, Merck & Co for new trial
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Imugene partners with multi billion dollar global pharma company, Merck & Co for new trial
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Imugene partners with multi billion dollar global pharma company, Merck & Co for new trial
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Imugene partners with multi billion dollar global pharma company, Merck & Co for new trial
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Noxopharm’s pancreatic cancer treatment drug slows tumour growth in mice, study shows
    Noxopharm’s pancreatic cancer treatment drug slows tumour growth in mice, study shows
    • News

  • FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    • News

  • Starpharma’s DEP shows promising results on prostate cancer patients
    Starpharma’s DEP shows promising results on prostate cancer patients
    • News

  • This article is like The Magic School Bus
    This article is like The Magic School Bus
    • News

  • Imugene partners with multi billion dollar global pharma company, Merck & Co for new trial
    Imugene partners with multi billion dollar global pharma company, Merck & Co for new trial
    • News

  • Imugene partners with multi billion dollar global pharma company, Merck & Co for new trial
    • News

    Imugene partners with multi billion dollar global pharma company, Merck & Co for new trial

    Since securing a European patent for their proprietary cancer vaccine HER-Vaxx, Imugene (ASX: IMU) have been busy. The Company has now announced the initiation of new clinical trials  in collaboration with global pharmaceutical company, Merck & Co (NYSE: MRK). The USD $46 billion company will support Imugene in evaluating the efficacy and safety of HER-Vaxx

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.